Astathera, officially known as Alpha Nuclide (Ningbo) Medical Technology Co., Ltd., specializes in the research and development of medical isotopes and radiopharmaceuticals. The company is focused on providing innovative diagnostic and therapeutic solutions, particularly in the field of radiotheranostics, which combines radiation therapy with diagnostic imaging. Astathera utilizes advanced alpha nuclide technology, specifically the 211At-α technology, to facilitate precision medicine for cancer treatment, aiming to offer new hope to patients through targeted therapies.

The company has established a production base in Haiyan, Zhejiang Province, where it has invested in two 30MeV cyclotron particle accelerators, set to commence operations in 2024. This facility will enable the commercial supply of a range of novel medical isotopes. Astathera's commitment to innovation is further underscored by its strategic partnerships and ongoing development efforts, positioning it as a leader in the nuclear pharmaceutical sector. The company is dedicated to building a world-class platform for the development of nuclear pharmaceuticals, emphasizing its mission to enhance health through scientific advancements.

China

Developer of targeted radionuclide therapies used to treat cancer. The company develops radioactive drugs and other nuclear therapies.

Astathera

Company Details